An X-ray or NMR structure of the target protein, preferably with a bound ligand, is considered to be a highly desirable feature of any drug discovery project. To meet this need, Domainex works with its scientific founders, who are world-leaders in structural biology, to deliver structural information to its clients. This information can then be used in virtual hit screening or to further guide medicinal chemistry efforts in later stages of drug discovery programs.
Following the production of drug target protein using Domainex’s Combinatorial Domain Hunting technology, Domainex works with Prof. Laurence Pearl FRS (Professor of Structural Biology at the University of Sussex and CSO of Domainex), in order to deliver high resolution crystal structures of the target protein of interest.
The Pearl Laboratory is one of the UK's leading Structural Biology Groups, having determined more than 30 new protein structures in the last 10 years, including major drug development targets such as Hsp90 and the protein kinases GSK3beta, Ire1 and CHK2. They specialize in determining the structures and mechanisms of some of the most challenging proteins and complexes, and have been at the forefront in contributing to technical developments such as CDH.
Within the Pearl laboratories, the process of structure solution is separated into 3 phases:
Once structural data is available, Domainex’s computational scientists are able to complete a virtual small molecule hit screen using its LeadBuilder software, to provide a focussed screening set of hit-like molecules against the drug target of interest.
Domainex will manage this entire process and maintain good communication links with the client at all stages, so that the project is seamlessly and efficiently delivered.
Alternatively, please email email@example.com to contact Prof. Laurence Pearl directly.